Business

PepGen to Participate in Upcoming Investor Conferences

BOSTON, November 03, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences:

Pepgen Inc.November 3, 20251
PepGen to Participate in Upcoming Investor Conferences

About this update from Pepgen Inc.

BOSTON, November 03, 2025 --( BUSINESS WIRE )--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences: A webcast of each conference presentation will be available on the "Events & Presentations" page within the Investors section of the PepGen website at https://investors.pepgen.com/ . Replays of the webcasts will be available on the PepGen website for 90 days following the presentation dates. About PepGen PepGen Inc. is a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. For more information, please visit PepGen.com . Follow PepGen on LinkedIn and X . View source version on businesswire.com: https://www.businesswire.com/news/home/20251103011281/en/ Contacts Investor Contact Laurence Watts New Street Investor Relations [email protected] M edia Contact Julia Deutsch Lyra Strategic Advisory [email protected]

View stock analysis, news, and events for Pepgen Inc.

neurological diseasesPepGen Inc.Healthcare ConferenceHealthcare Innovation ConferenceoligonucleotideFireside Chatinvestor conferencesPepGenbiotechnology companyBUSINESS WIRE

More from Pepgen Inc.

All Pepgen Inc. news →